当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > The benzene metabolite, hydroquinone, induces dose-dependent hypoploidy in a human cell line.

The benzene metabolite, hydroquinone, induces dose-dependent hypoploidy in a human cell line.

Abstract：

:Chronic exposure to high concentrations of benzene can result in the development of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Studies of patients occupationally exposed to benzene show a pattern of cytogenetic aberrations involving high frequency of loss of all or part of chromosomes 5 and/or 7 as well as trisomy 8. The pattern of reoccurring chromosome abnormalities associated with the development of leukemia can be used as a guide in understanding the etiology and pathogenesis of these diseases. Therefore, a research project was designed to determine whether a metabolite of benzene, hydroquinone (HQ), could directly induce loss of chromosome 5 and/or 7 and gain of chromosome 8. Using fluorescence in situ hybridization with chromosome-specific 5, 7 and 8 probes we demonstrate that 42, 49 and 26 microM HQ induces monosomy 5, 7 and 8, respectively, in the human lymphoblast cell line GM09948. These results demonstrate for the first time that HQ induces a specific chromosome loss found in secondary MDS/AML. The pattern of chromosome 5 and/or 7 loss in benzene-induced MDS/AML is probably due to selective cell survival after HQ exposure rather than specific targeting of HQ for chromosomes 5 or 7.

journal_name

Leukemia

journal_title

Leukemia

authors

Stillman WS,Varella-Garcia M,Gruntmeir JJ,Irons RD

doi

10.1038/sj.leu.2400763

subject

Has Abstract

pub_date

1997-09-01 00:00:00

pages

1540-5

issue

9

eissn

0887-6924

issn

1476-5551

journal_volume

11

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia.

    abstract：:ATP-binding-cassette (ABC) transporters are evolutionary extremely well-conserved transmembrane proteins that are highly expressed in hematopoietic stem cells (HSCs). The physiological function in human stem cells is believed to be protection against genetic damage caused by both environmental and naturally occurring ...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2404859

    authors： Raaijmakers MH

    更新日期：2007-10-01 00:00:00

  • Biologic response modifiers in acute lymphoblastic leukemia.

    abstract：:Despite the presence of tumor antigens, the paucity of clinically significant T-cell mediated immune responses against human tumors is striking. This may, in part, be because of the inability of cancer cells to function as efficient antigen-presenting cells. For full activation, T cells must receive two signals delive...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Gribben JG,Cardoso AA,Schultze JL,Nadler LM

    更新日期：1997-05-01 00:00:00

  • Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.

    abstract：:PCR-based monitoring of minimal residual disease (MRD) in acute leukemias can be achieved via detection of fusion gene transcripts of chromosome aberrations or detection of immunoglobulin (Ig) and T cell receptor (TCR) gene rearrangements. We wished to assess whether both PCR targets are complementary in acute myeloid...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402387

    authors： Boeckx N,Willemse MJ,Szczepanski T,van der Velden VH,Langerak AW,Vandekerckhove P,van Dongen JJ

    更新日期：2002-03-01 00:00:00

  • De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance.

    abstract：:Dysplastic hematopoiesis is the morphological hallmark of myelodysplastic syndromes. Dysplastic features in one or more lineages are also found frequently in bone marrow aspirates from patients with de novo AML and have been associated with an unfavorable prognosis. We asked whether dyshematopoiesis is an independent ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Gahn B,Haase D,Unterhalt M,Drescher M,Schoch C,Fonatsch C,Terstappen LW,Hiddemann W,Büchner T,Bennett JM,Wörmann B

    更新日期：1996-06-01 00:00:00

  • BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.

    abstract：:Bruton agammaglobulinemia tyrosine kinase (BTK), a cytoplasmic protein tyrosine kinase, is a component of the B-cell receptor signaling pathway. Ibrutinib, a BTK inhibitor, has demonstrated a significant clinical activity against chronic lymphocytic leukemia (CLL) in early clinical trials. Understanding the molecular ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.358

    authors： Cheng S,Ma J,Guo A,Lu P,Leonard JP,Coleman M,Liu M,Buggy JJ,Furman RR,Wang YL

    更新日期：2014-03-01 00:00:00

  • De novo gene mutations in normal human memory B cells.

    abstract：:In the past years, the genomes of thousands of tumors have been elucidated. To date however, our knowledge on somatic gene alterations in normal cells is very limited. In this study, we demonstrate that tetanus-specific human memory B lymphocytes carry a substantial number of somatic mutations in the coding regions of...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0289-4

    authors： Slot LM,Wormhoudt TAM,Kwakkenbos MJ,Wagner K,Ballering A,Jongejan A,van Kampen ACM,Guikema JEJ,Bende RJ,van Noesel CJM

    更新日期：2019-05-01 00:00:00

  • Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.

    abstract：:Small-molecule multi-targeted cyclin-dependent kinase (CDK) inhibitors (CDKIs) are of particular interest due to their potent antitumor activity independent of p53 gene alterations. P53 deletion is associated with a very poor prognosis in multiple myeloma (MM). In this regard, we tested the anti-MM activity of RGB-286...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.194

    authors： Cirstea D,Hideshima T,Santo L,Eda H,Mishima Y,Nemani N,Hu Y,Mimura N,Cottini F,Gorgun G,Ohguchi H,Suzuki R,Loferer H,Munshi NC,Anderson KC,Raje N

    更新日期：2013-12-01 00:00:00

  • Bone marrow stem cell mobilization in stroke: a 'bonehead' may be good after all!

    abstract：:Mobilizing bone cells to the head, astutely referred to as 'bonehead' therapeutic approach, represents a major discipline of regenerative medicine. The last decade has witnessed mounting evidence supporting the capacity of bone marrow (BM)-derived cells to mobilize from BM to peripheral blood (PB), eventually finding ...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2011.167

    authors： Borlongan CV

    更新日期：2011-11-01 00:00:00

  • Clinical significance of chromosome abnormalities in childhood acute lymphoblastic leukemia in Japan.

    abstract：:Of 240 Japanese children with acute lymphoblastic leukemia (ALL) treated between 1983 and 1990, 75 (31%) had normal diploidy, 47 (20%) hyperdiploidy with more than 50 chromosomes, 18 (8%) hyperdiploidy with 47-50 chromosomes, 77 (32%) pseudodiploidy, 22 (9%) hypodiploidy and one hypotetraploidy in the leukemic cells. ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Kobayashi H,Maseki N,Homma C,Sakurai M,Kaneko Y

    更新日期：1994-11-01 00:00:00

  • A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.

    abstract：:This study was undertaken to determine the efficacy and toxicity of a shorter schedule of fludarabine administration (30 mg/m2 i.v. daily for 3 days every 4 weeks) in patients with previously treated chronic lymphocytic leukemia (CLL). Eighty patients with previously treated advanced (Rai III-IV) (54%) or progressive ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Robertson LE,O'Brien S,Kantarjian H,Koller C,Beran M,Andreeff M,Lerner S,Plunkett W,Keating MJ

    更新日期：1995-09-01 00:00:00

  • Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation.

    abstract：:Lack of apoptosis has been linked to prolonged survival of malignant B cells expressing bcl-2. The aim of the present study was to analyze the amount of bcl-2 protein expressed along normal human B-cell maturation and to establish the frequency of aberrant bcl-2 expression in B-cell malignancies. In normal bone marrow...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403231

    authors： Menendez P,Vargas A,Bueno C,Barrena S,Almeida J,De Santiago M,López A,Roa S,San Miguel JF,Orfao A

    更新日期：2004-03-01 00:00:00

  • Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report.

    abstract：:One-hundred, twenty-eight patients with Hodgkin's disease in remission or who had failed a mechlorethamine, vincristine, procarbazine and prednisone (MOPP), a doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and/or lomustine, etoposide and prednimustine (CEP) regimens have been treated with a high-dose thera...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Carella Am,Carlier P,Congiu A,Occhini D,Meloni G,Anselmo AP,Mandelli F,Mazza P,Tura S,Mangoni L

    更新日期：1991-01-01 00:00:00

  • Human bone marrow cytogenetics: growth factors stimulate metaphases for specific lineages.

    abstract：:Fresh and/or frozen bone marrow cells from five healthy individuals and seven patients with myeloid leukemia were studied using growth factors and a cytogenetic technique which allows simultaneous analysis of karotype and cell lineage. Cell lineages were identified using monoclonal antibodies in an alkaline phosphatas...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Keinänen M,Bloomfield CD,Machnicki J,Griffin JD,de la Chapelle A

    更新日期：1989-06-01 00:00:00

  • CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

    abstract：:The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed "minimal residual disease". The phenomenon of disease persistence suggests that despite tar...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0684-5

    authors： Kinstrie R,Horne GA,Morrison H,Irvine D,Munje C,Castañeda EG,Moka HA,Dunn K,Cassels JE,Parry N,Clarke CJ,Scott MT,Clark RE,Holyoake TL,Wheadon H,Copland M

    更新日期：2020-06-01 00:00:00

  • Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome.

    abstract：:Mutations of the GATA1 gene on chromosome X have been found in almost all cases of transient myeloproliferative disorder and acute megakaryoblastic leukemia (AMKL) accompanying Down syndrome (DS). Although most GATA1 mutations lead to the expression of GATA1s lacking the N-terminal activation domain, we recently found...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404223

    authors： Xu G,Kanezaki R,Toki T,Watanabe S,Takahashi Y,Terui K,Kitabayashi I,Ito E

    更新日期：2006-06-01 00:00:00

  • Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.

    abstract：:In this study, we compared immunoglobulin heavy-chain-gene-based minimal residual disease (MRD) detection by real-time quantitative PCR (RQ-PCR) and next-generation sequencing (NGS) to assess whether NGS could overcome some limitations of RQ-PCR and further increase sensitivity, specificity, accuracy and reproducibili...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.375

    authors： Ladetto M,Brüggemann M,Monitillo L,Ferrero S,Pepin F,Drandi D,Barbero D,Palumbo A,Passera R,Boccadoro M,Ritgen M,Gökbuget N,Zheng J,Carlton V,Trautmann H,Faham M,Pott C

    更新日期：2014-06-01 00:00:00

  • 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.

    abstract：:14-3-3 proteins are a family of master regulators of intracellular signaling, yet their impact on proteasome function is unknown. We demonstrate that 14-3-3ζ binds the 11S proteasome activator, limiting proteasome assembly and cellular capacity for protein degradation. To define the functional impact of 14-3-3ζ protea...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.288

    authors： Gu Y,Xu K,Torre C,Samur M,Barwick BG,Rupji M,Arora J,Neri P,Kaufman J,Nooka A,Bernal-Mizrachi L,Vertino P,Sun SY,Chen J,Munshi N,Fu H,Kowalski J,Boise LH,Lonial S

    更新日期：2018-03-01 00:00:00

  • Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia.

    abstract：:We have analysed the structure of the T-cell receptor gamma chain (TCRG) genes in a panel of biopsies taken from 24 patients with acute lymphoblastic leukemia (ALL) (13 cALL, one pre-B ALL, two null ALL and eight T-ALL) at presentation and at clinical relapse. In the majority of cases (18/24) the structure of these ge...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Taylor JJ,Rowe D,Kylefjord H,Chessells J,Katz F,Proctor SJ,Middleton PG

    更新日期：1994-01-01 00:00:00

  • Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.

    abstract：:An antisense oligodeoxynucleotide (ODN) complementary to the first six codons of the Bcl-2 mRNA, G3139 (oblimersen sodium; Genasense), has been shown to downregulate Bcl-2 and produce responses in a variety of malignancies including drug-resistant lymphoma. Incubation of ex vivo purified plasma cells from patients wit...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402768

    authors： van de Donk NW,Kamphuis MM,van Dijk M,Borst HP,Bloem AC,Lokhorst HM

    更新日期：2003-01-01 00:00:00

  • Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma.

    abstract：:Long-term disease-free survival following conventional cytotoxic therapy is extremely rare in patients with advanced-stage mantle cell lymphoma (MCL). High-dose conditioning therapy consisting of hyperfractionated total body irradiation (TBI, 14.4 Gy) and cyclophosphamide (200 mg/kg) was therefore offered to 13 patien...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：

    authors： Haas R,Brittinger G,Meusers P,Murea S,Goldschmidt H,Wannenmacher M,Hunstein W

    更新日期：1996-12-01 00:00:00

  • Establishment and characterization of a murine megakaryoblastic cell line growing in protein-free culture (L8057Y5).

    abstract：:A murine megakaryoblastic cell line growing in protein-free culture (L8057Y5) was established from an experimentally induced murine leukemia (MK8057). Most of the Y5 cells were small and blast-like, with 2-4N in DNA content. Also, large cells possessing a lobulated nucleus characteristic of megakaryocytes, which showe...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Sasaki H,Kajigaya Y,Hirabayashi Y,Funabiki T,Inoue T,Yokota T,Ikuta K,Arai K,Matsuyama S

    更新日期：1991-05-01 00:00:00

  • Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia.

    abstract：:Donor leukocyte infusions (DLI) have turned out to be an efficient way to re-establish complete remission (CR) in chronic myeloid leukemia (CML) patients relapsing after allogeneic bone marrow transplantation (BMT). In these patients, absence of PCR bcr-abl fusion transcripts confirmed the potency of donor leukocytes ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401144

    authors： Berthou C,Léglise MC,Herry A,Balcon D,Hardy E,Lessard M,Abgrall JF

    更新日期：1998-11-01 00:00:00

  • LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.

    abstract：:LSD1 has emerged as a promising epigenetic target in the treatment of acute myeloid leukemia (AML). We used two murine AML models based on retroviral overexpression of Hoxa9/Meis1 (H9M) or MN1 to study LSD1 loss of function in AML. The conditional knockout of Lsd1 resulted in differentiation with both granulocytic and...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0375-7

    authors： Barth J,Abou-El-Ardat K,Dalic D,Kurrle N,Maier AM,Mohr S,Schütte J,Vassen L,Greve G,Schulz-Fincke J,Schmitt M,Tosic M,Metzger E,Bug G,Khandanpour C,Wagner SA,Lübbert M,Jung M,Serve H,Schüle R,Berg T

    更新日期：2019-06-01 00:00:00

  • Increased levels of interleukin-6 (IL-6) in serum and spontaneous in vitro production of IL-6 by lymph node mononuclear cells of patients with angio-immunoblastic lymphadenopathy with dysproteinemia (AILD), and clinical effectiveness of cyclosporin A.

    abstract：:Serum levels of cytokines and in vitro cytokine production by lymph node mononuclear cells (LNMC) were studied in four patients with angio-immunoblastic lymphadenopathy with dysproteinemia (AILD) or AILD-type T cell lymphoma. An increased level of serum interleukin-6 (IL-6) was detected on initial diagnosis in both of...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Yamamura M,Honda M,Yamada Y,Itoyama T,Sohda H,Yubashi T,Momita S,Kamihira S,Ohmoto Y,Tomonaga M

    更新日期：1996-09-01 00:00:00

  • Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.

    abstract：:We investigated the hypothesis that gemtuzumab ozogamicin (GO), an anti-CD33 immunotoxin would improve the efficacy of fludarabine/melphalan as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial. Toxicity was defined as grades III-IV organ damage, engraftment fail...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2405014

    authors： de Lima M,Champlin RE,Thall PF,Wang X,Martin TG 3rd,Cook JD,McCormick G,Qazilbash M,Kebriaei P,Couriel D,Shpall EJ,Khouri I,Anderlini P,Hosing C,Chan KW,Andersson BS,Patah PA,Caldera Z,Jabbour E,Giralt S

    更新日期：2008-02-01 00:00:00

  • Acute B-lymphocytic leukemia with L1 morphology: a report of two pediatric cases.

    abstract：:Two pediatric cases of acute lymphoblastic leukemia with L1 morphology who also demonstrated immunoglobulin on the leukemic cell surface are presented. The first patient's disease progressed on standard induction therapy, despite the presence of good prognostic features at presentation. The second patient has achieved...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Finlay JL,Borcherding W

    更新日期：1988-01-01 00:00:00

  • Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy.

    abstract：:This study investigated the relationships between HDL-C and major types of blood cancers. Competing risks regression was used to examine the hazard ratios of hematologic malignancies in 9,596,145 individuals (≥20 years) using data from the Korean National Health Insurance Service (2009-2017). The incidence of the foll...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-01081-5

    authors： Jeong SM,Choi T,Kim D,Han K,Kim SJ,Rhee SY,Giovannucci EL,Shin DW

    更新日期：2020-12-02 00:00:00

  • Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.

    abstract：:The fusion transcript AML1/ETO corresponding to translocation t(8;21)(q22;q22) can be found in approximately 7-12% of childhood de novo AML. Despite the favorable prognosis, some of these patients relapse. Most of MRD studies so far were performed on adults treated not uniformly. Therefore, we analyzed the follow-up o...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.leu.2402959

    authors： Viehmann S,Teigler-Schlegel A,Bruch J,Langebrake C,Reinhardt D,Harbott J

    更新日期：2003-06-01 00:00:00

  • Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.

    abstract：:Targeted therapies are frequently combined with standard cytotoxic drugs to enhance clinical response. Targeting the B-cell lymphoma 2 (BCL-2) family of proteins is an attractive option to combat chemoresistance in leukemia. Preclinical and clinical studies indicate modest single-agent activity with selective BCL-2 in...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.243

    authors： Teh TC,Nguyen NY,Moujalled DM,Segal D,Pomilio G,Rijal S,Jabbour A,Cummins K,Lackovic K,Blombery P,Thompson E,Ekert PG,Lessene G,Glaser SP,Huang DCS,Roberts AW,Guthridge MA,Wei AH

    更新日期：2018-02-01 00:00:00

  • Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

    abstract：:Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are frequently found in several human cancer types including acute myeloid leukemia (AML) and lead to the production of high levels of the oncometabolite (R)-2-hydroxyglutarate (R-2HG). Here we report the characterization of BAY1436032, a novel pan-mutant IDH1 ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.46

    authors： Chaturvedi A,Herbst L,Pusch S,Klett L,Goparaju R,Stichel D,Kaulfuss S,Panknin O,Zimmermann K,Toschi L,Neuhaus R,Haegebarth A,Rehwinkel H,Hess-Stumpp H,Bauser M,Bochtler T,Struys EA,Sharma A,Bakkali A,Geffers R,Ara

    更新日期：2017-10-01 00:00:00